Insights drawing from historical metrics that optimize pre- and post-commercialization marketing efforts for new therapies.
A discussion of how the proposed ruling on copay accumulators will impact more than just the bottom line for both pharma and patients.
Get the most out of
Register for free and enjoy unlimited access to:
